Mirum Pharmaceuticals, Inc., a biopharmaceutical company, is focused on the development and commercialization of an advanced line of novel therapies for debilitating liver diseases. The company is headquartered in Foster City, California.
| Revenue (TTM) | $521.31M |
| Gross Profit (TTM) | $421.07M |
| EBITDA | $2.11M |
| Operating Margin | -3.07% |
| Return on Equity | -8.65% |
| Return on Assets | -1.83% |
| Revenue/Share (TTM) | $10.38 |
| Book Value | $6.06 |
| Price-to-Book | 18.86 |
| Price-to-Sales (TTM) | 11.38 |
| EV/Revenue | 11.26 |
| EV/EBITDA | 341.15 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 49.80% |
| Shares Outstanding | $60.98M |
| Float | $52.43M |
| % Insiders | 1.36% |
| % Institutions | 104.56% |
Volatility is currently expanding